Infliximab as a therapy for idiopathic hypereosinophilic syndrome

Archives of Dermatology

Volumn 143, Issue 9, 2007, Pages 1110-1112

  Taverna, Josephine A ^a   Lerner, Adam ^a   Goldberg, Lynne ^a   Werth, Stephen ^b   Demierre, Marie France ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; CORTICOSTEROID; DENILEUKIN DIFTITOX; DEXAMETHASONE; FLUDARABINE PHOSPHATE; IMATINIB; INFLIXIMAB; ISOTRETINOIN; MITOXANTRONE; PSORALEN;

ABSENCE OF SIDE EFFECTS; AGED; ARTICLE; CASE REPORT; CHILL; ERYTHRODERMA; FATIGUE; FEMALE; HUMAN; HUMAN TISSUE; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; KERATODERMA; MALAISE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PRURITUS; RASH; TREATMENT RESPONSE; WEIGHT REDUCTION;

AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; HYPEREOSINOPHILIC SYNDROME; SKIN DISEASES;

EID: 34548858481     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.143.9.1110     Document Type: Article

References (18)

1. Chusid MJ, Dale DC, West BC, Wolff SM. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine (Baltimore). 1975;54(1):1-27.
2. Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol. 2003;121(2):203-223.
3. Tefferi A. Blood eosinophilias: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc. 2005;80(1):75-83.
4. Roufosse F, Cogan E, Goldman M. Recent advances in pathogenesis and management of hypereosinophilic syndromes. Allergy. 2004;59(7):673-689.
5. Sutton SA, Ass'ad AH, Rothenberg ME. Anti-IL-5 and hypereosinophilic syndromes. Clin Immunol. 2005;115(1):51-60.
6. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201- 1214.
7. Yoon TY, Ahn GB, Chang SH. Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review. J Dermatol. 2000;27(2):110-115.
8. Ueno NT, Anagnostopoulos A, Rondon G, et al. Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome. Br J Haematol. 2002;119(1):131-134.
9. Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). Ann Rheum Dis. 2004;63(3):232.
10. O'Quinn RP, Miller JL. The effectiveness of tumor necrosis factor alpha antibody (infliximab) in treating recalcitrant psoriasis: a report of two cases. Arch Dermatol. 2002;138(5):644-648.
11. Winterfield LS, Menter A, Gordon K, Gottlieb A. Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis. 2005;64(suppl 2):ii87-ii92.
12. Liao WC, Mutasim DF. Infliximab for the treatment of adult-onset pityriasis rubra pilaris. Arch Dermatol. 2005;141(4):423-425.
13. Bochner BS, Luscinskas FW, Gimbrone MA, Newman W. Adhesion of human basophils, eosinophils and neutrophils to interleukin 1-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J Exp Med. 1991;173(6):1553-1557.
14. Kyan-Aung U, Haskard DO, Poston RN, Thornhill MH, Lee TH. Endothelial leukocyte adhesion molecule-1 and intercellular adhesion molecule-1 mediate the adhesion of eosinophils to endothelial cells in vitro and are expressed by endothelium in allergic cutaneous inflammation in vivo. J Immunol. 1991;146(2):521-528.
15. Weller PF, Rand TH, Goelz SE, Chi-Rosso G, Lobb RR. Human eosinophil adherence to vascular endothelium mediated by binding to vascular cell adhesion molecule 1 and endothelial leukocyte adhesion molecule 1. Proc Natl Acad Sci U S A. 1991;88(16):7430-7433.
16. Williams IR, Kupper TS. Immunity at the surface: homeostatic mechanisms of the skin immune system. Life Sci. 1996;58(18):1485-1507.
17. Costa JJ, Matossian K, Resnick MB, et al. Human eosinophils can express the cytokines tumor necrosis factor alpha and macrophage inflammatory protein-1 alpha. J Clin Invest. 1993;91(6):2673-2684.
18. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295(19):2275-2285.